-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*It is only for medical professionals to read for reference.
The future of lupus treatment is bright! Systemic lupus erythematosus (SLE) is a classic autoimmune disease with strong heterogeneity, which brings great challenges to the diagnosis and treatment of the disease.
With the development of the discipline, the prognosis of lupus patients in my country has improved significantly.
In the past year, what new achievements have been made in the field of lupus in my country? What changes will these results bring to the diagnosis and treatment of lupus? The medical community talked with Professor Feng Xuebing from the Department of Rheumatology and Immunology, Drum Tower Hospital, Nanjing University School of Medicine, to discuss this issue.
2020 Lupus Events: The official release of the new guidelines mentions the most impressive "events" in the field of lupus in 2020.
Professor Feng Xuebing's first thought was the release of the "2020 China Systemic Lupus Erythematosus Guidelines".
This is the first update of the Lupus Guidelines in ten years after the "Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus" promulgated by the Chinese Medical Association in 2010.
The new version of the guidelines is clinically problem-oriented, based on evidence-based medicine, based on cutting-edge results, combined with actual national conditions, and put forward recommendations on 12 clinical problems that the majority of rheumatologists are concerned about.
In addition, in 2019, the European Union Against Rheumatism (EULAR) successively updated the management recommendations for systemic lupus erythematosus and the management recommendations for lupus nephritis.
In November, the new version of the Chinese Lupus Nephritis Diagnostic and Treatment Guidelines was officially released.
Professor Feng Xuebing believes: "The domestic and international lupus guidelines have been updated successively, indicating that people are paying more and more attention to lupus in recent years.
Especially the release of the new domestic guidelines, based on the quotation of the latest evidence, also considers China's national conditions, and works for more grassroots levels.
The authors provided reasonable and standardized guidelines, which is a good start for the implementation and promotion of standardized diagnosis and treatment.
"The 5-year survival rate of SLE patients in China has increased from 50% to 60% in the 1950s to more than 90%.
Lupus patients Survival has been greatly improved [1]."However, data from a large retrospective study in Jiangsu Province shows that the prognosis of severely ill patients with lupus is still not optimistic.
How to identify critically ill patients early, give standardized treatment, and improve the prognosis is a problem that our clinicians pay special attention to.
" Professor Feng Xuebing said.
The new version of the guidelines points out that for patients with lupus who are newly diagnosed and followed up, it is recommended to select the SLE Disease Activity Index (SLEDAI-2000) scoring standard and combine the comprehensive judgment of the clinician to evaluate the disease activity.
For patients with lupus in the active stage of disease, it is recommended to assess the disease activity at least once every 1 month, and for patients in the stable stage of disease, it is recommended to assess the disease activity once every 3 to 6 months.
In addition, the frequency of clinical monitoring needs to be adjusted according to the evolution of the disease and the intensity of treatment.
New drugs emerge to help fight the "wolf" In the new century, a wide variety of biological agents and targeted drugs have sprung up, such as rheumatoid arthritis, ankylosing spondylitis and other rheumatic immune diseases.
The renewal of treatment methods has brought tremendous changes to disease management.
"Lupus treatment is also walking along this road, although it is slower, but there are already signs of success.
" Professor Feng Xuebing said.
As we all know, the research and development of new drugs in the field of lupus is relatively difficult, and many drugs have failed in the third phase of clinical studies.
Until 2011, the world's first biologic agent belyumumab for the treatment of SLE was approved by the U.
S.
Food and Drug Administration (FDA), becoming the first new drug approved for SLE in 60 years.
In 2019, belyumumab was launched in China, and in 2020, it will be approved for children's SLE indications in China, and the applicable population will be expanded to patients over 5 years old.
In the PLUTO study and the BLISS-LN study, researchers explored the efficacy and safety of beliyuumab in the treatment of children with SLE and lupus nephritis.
The latest results were released at the 2020 EULAR annual meeting [2-4], which is a biological preparation Applying to the treatment of lupus adds new evidence. In March 2021, China's domestically produced new drug biologic tytazep was approved in China.
Tatazep is a fusion protein drug that can act on BLyS and APRIL at the same time, reducing the autoimmune response mediated by B cells and alleviating the symptoms of SLE.
.
The advent of domestically-made innovative drugs marks that my country has taken the lead in the world in the research and development of new lupus drugs, and has further enriched the treatment options for lupus patients.
Professor Feng Xuebing said optimistically: “In addition to the two approved biologics, there are more
new drugs with different targets under development.
The advent of new drugs and the concept of reaching standards can help us better treat patients and improve Prognosis.
I think the prospects for the treatment of lupus are bright.
" Professor Feng Xuebing, Chief Physician and Professor, Deputy Chief Executive of the Department of Rheumatology and Immunology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Jiangsu Province 12th and 13th Five-Year Medical Key Talents Chinese Medical Association Member of Rheumatology Branch, Chairman of Rheumatology Branch of Jiangsu Medical Association, Vice President of Rheumatology Branch of Jiangsu Medical Association, Vice Chairman of Rheumatology Branch of Jiangsu Integrative Medicine Association, Cross-Strait Medicine and Health Exchange Association Rheumatology Committee Psoriatic Arthritis Group Standing Committee Member of the Chinese Journal of Rheumatology Newsletter Editorial Board Reference: [1] Chinese Medical Association Rheumatology Branch; Chinese Journal of Internal Medicine; 2020;59(3):172-185.
[2]N.
Ruperto,et al.
EULAR Annual Meeting,June 3-6,2020,SAT0505.
[3]N.
Ruperto,et al.
EULAR Annual Meeting,June 3-6,2020,THU0503.
[4]R.
Furie,et al .
EULAR Annual Meeting, June 3-6, 2020, OP0164.
The future of lupus treatment is bright! Systemic lupus erythematosus (SLE) is a classic autoimmune disease with strong heterogeneity, which brings great challenges to the diagnosis and treatment of the disease.
With the development of the discipline, the prognosis of lupus patients in my country has improved significantly.
In the past year, what new achievements have been made in the field of lupus in my country? What changes will these results bring to the diagnosis and treatment of lupus? The medical community talked with Professor Feng Xuebing from the Department of Rheumatology and Immunology, Drum Tower Hospital, Nanjing University School of Medicine, to discuss this issue.
2020 Lupus Events: The official release of the new guidelines mentions the most impressive "events" in the field of lupus in 2020.
Professor Feng Xuebing's first thought was the release of the "2020 China Systemic Lupus Erythematosus Guidelines".
This is the first update of the Lupus Guidelines in ten years after the "Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus" promulgated by the Chinese Medical Association in 2010.
The new version of the guidelines is clinically problem-oriented, based on evidence-based medicine, based on cutting-edge results, combined with actual national conditions, and put forward recommendations on 12 clinical problems that the majority of rheumatologists are concerned about.
In addition, in 2019, the European Union Against Rheumatism (EULAR) successively updated the management recommendations for systemic lupus erythematosus and the management recommendations for lupus nephritis.
In November, the new version of the Chinese Lupus Nephritis Diagnostic and Treatment Guidelines was officially released.
Professor Feng Xuebing believes: "The domestic and international lupus guidelines have been updated successively, indicating that people are paying more and more attention to lupus in recent years.
Especially the release of the new domestic guidelines, based on the quotation of the latest evidence, also considers China's national conditions, and works for more grassroots levels.
The authors provided reasonable and standardized guidelines, which is a good start for the implementation and promotion of standardized diagnosis and treatment.
"The 5-year survival rate of SLE patients in China has increased from 50% to 60% in the 1950s to more than 90%.
Lupus patients Survival has been greatly improved [1]."However, data from a large retrospective study in Jiangsu Province shows that the prognosis of severely ill patients with lupus is still not optimistic.
How to identify critically ill patients early, give standardized treatment, and improve the prognosis is a problem that our clinicians pay special attention to.
" Professor Feng Xuebing said.
The new version of the guidelines points out that for patients with lupus who are newly diagnosed and followed up, it is recommended to select the SLE Disease Activity Index (SLEDAI-2000) scoring standard and combine the comprehensive judgment of the clinician to evaluate the disease activity.
For patients with lupus in the active stage of disease, it is recommended to assess the disease activity at least once every 1 month, and for patients in the stable stage of disease, it is recommended to assess the disease activity once every 3 to 6 months.
In addition, the frequency of clinical monitoring needs to be adjusted according to the evolution of the disease and the intensity of treatment.
New drugs emerge to help fight the "wolf" In the new century, a wide variety of biological agents and targeted drugs have sprung up, such as rheumatoid arthritis, ankylosing spondylitis and other rheumatic immune diseases.
The renewal of treatment methods has brought tremendous changes to disease management.
"Lupus treatment is also walking along this road, although it is slower, but there are already signs of success.
" Professor Feng Xuebing said.
As we all know, the research and development of new drugs in the field of lupus is relatively difficult, and many drugs have failed in the third phase of clinical studies.
Until 2011, the world's first biologic agent belyumumab for the treatment of SLE was approved by the U.
S.
Food and Drug Administration (FDA), becoming the first new drug approved for SLE in 60 years.
In 2019, belyumumab was launched in China, and in 2020, it will be approved for children's SLE indications in China, and the applicable population will be expanded to patients over 5 years old.
In the PLUTO study and the BLISS-LN study, researchers explored the efficacy and safety of beliyuumab in the treatment of children with SLE and lupus nephritis.
The latest results were released at the 2020 EULAR annual meeting [2-4], which is a biological preparation Applying to the treatment of lupus adds new evidence. In March 2021, China's domestically produced new drug biologic tytazep was approved in China.
Tatazep is a fusion protein drug that can act on BLyS and APRIL at the same time, reducing the autoimmune response mediated by B cells and alleviating the symptoms of SLE.
.
The advent of domestically-made innovative drugs marks that my country has taken the lead in the world in the research and development of new lupus drugs, and has further enriched the treatment options for lupus patients.
Professor Feng Xuebing said optimistically: “In addition to the two approved biologics, there are more
new drugs with different targets under development.
The advent of new drugs and the concept of reaching standards can help us better treat patients and improve Prognosis.
I think the prospects for the treatment of lupus are bright.
" Professor Feng Xuebing, Chief Physician and Professor, Deputy Chief Executive of the Department of Rheumatology and Immunology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Jiangsu Province 12th and 13th Five-Year Medical Key Talents Chinese Medical Association Member of Rheumatology Branch, Chairman of Rheumatology Branch of Jiangsu Medical Association, Vice President of Rheumatology Branch of Jiangsu Medical Association, Vice Chairman of Rheumatology Branch of Jiangsu Integrative Medicine Association, Cross-Strait Medicine and Health Exchange Association Rheumatology Committee Psoriatic Arthritis Group Standing Committee Member of the Chinese Journal of Rheumatology Newsletter Editorial Board Reference: [1] Chinese Medical Association Rheumatology Branch; Chinese Journal of Internal Medicine; 2020;59(3):172-185.
[2]N.
Ruperto,et al.
EULAR Annual Meeting,June 3-6,2020,SAT0505.
[3]N.
Ruperto,et al.
EULAR Annual Meeting,June 3-6,2020,THU0503.
[4]R.
Furie,et al .
EULAR Annual Meeting, June 3-6, 2020, OP0164.
